Enterovirus-A71 (EV-A71) is an etiological agent of the hand, foot and mouth disease (HFMD). EV-A71 infection produces high fever and ulcers in children. Some EV-A71 strains produce severe infections leading to pulmonary edema and death. Although the protective efficacy of the inactivated vaccine (IV) was ≥ 90% against mild HFMD, there was approximately 80% protection against severe HFMD. The monovalent EV-A71 IV elicits humoral immunity but lacks long-term immunogenicity. Spontaneous mutations of the EV-A71 genome could lead to antigenicity changes and the virus may not be neutralized by antibodies elicited by the IV. A better alternative would be the live attenuated vaccine (LAV) that elicits cellular and humoral immunity. The LAV induces excellent antigenicity and chances of reversion is reduced by presence of multiple mutations which could reduce pathogenicity. Besides CV-A16, outbreaks have been caused by CV-A6 and CV-A10, hence the development of bivalent and trivalent vaccines is required.
Introduction
Enteroviruses are associated with a plethora of infections that pose significant health problems in the post-poliovirus eradication era. The clinical symptoms can range from mild seasonal flulike illness and mild hand, foot and mouth disease (HFMD) to potentially fatal conditions, such as acute flaccid paralysis and pulmonary edema (1) Most of the enteroviruses have no vaccine or antivirals against them. There should be continuous efforts to develop vaccines to accelerate eradication of enteroviral diseases. Of particular interest in this review would be EV-A71 which is considered the most important neurotropic enterovirus after the eradication of Poliovirus (8) . The EV-A71 virus consists of a single-stranded, positive sense, ribonucleic acid (RNA) of approximately 7411 base pairs long.
The RNA has an open reading frame (ORF) that is flanked by the 5' and 3' Non-Translated Regions (NTRs) (9) . The 5'-NTR contains the Internal Ribosome Entry site (IRES) that allows mRNA translation in a cap-independent manner (10) . The ORF (P1-P3) is translated into a single polyprotein that undergoes a series of processing events, that eventually is cleaved to structural and non-structural viral proteins (11) .
The 4 viral capsid proteins (VP1, VP2, VP3, and VP4) are structural proteins and they are encoded by the P1 region. VP1, VP2 and VP3 are exposed on the external surface of the EV-A71 virus whereas VP4 is located on the internal side of the capsid. The nonstructural proteins involved in genome replication and protein processing (2A-2C, 3A-3D) are encoded by the P2 and P3 regions (12) . The 2A and 3C proteinases are vital for virus-host interactions, virus replication and apoptosis of infected cells in vitro (13, 14) . As the 3D protein is a RNAdependent RNA polymerase (RdRP) that lacks proofreading mechanism, this led to high mutation rates of 10 -3 to 10 -5 mutations per nucleotide copied, per replication cycle (15) . Hence, it is known to mis-incorporate 1 or 2 bases for every genome replication (16) .
Etiology of HFMD
The EV-A71 virus was first isolated from a child in California, United States in 1969 (17) . Based on a 5-year surveillance in China (2008) (2009) (2010) (2011) (2012) (2013) (2014) , approximately 43.73%, 22.04%, and 34.22% of HFMD infections were due to EV-A71, CV-A16 and other enteroviruses, respectively. Amongst all etiological agents of fatal HFMD infections, EV-A71 was responsible for 70% severe HFMD cases and 90% HFMD-related deaths (18) . Mild EV-71 infection in children are fever (≥ 39 o C), loss of appetite with rashes (hands, foot and mouth area) and ulcers in the throat, mouth and tongue. However, some sub-genotypes of EV-A71 strains (B3, B4, C4) have been associated with more severe clinical infections which could lead to delayed neurodevelopment, aseptic meningitis, brain stem encephalitis, acute flaccid paralysis, neurogenic pulmonary edema and cardiopulmonary failure (1).
The neurological complications of EV-A71 have led to high fatalities in countries such as China, Malaysia, Taiwan, Vietnam and Cambodia (19) . For example, in Taiwan in 1998, there were 129,106 reported cases of HFMD and 405 severe cases with 34 deaths due to EV-A71 (20) . In Cambodia alone, there was approximately 69% fatalities out of 78 infections between April and July 2012 (21) . Some of the young children died of alveolar pneumonia, while others developed fatal destructive brain and spinal cord inflammation caused by fatal sub-genotypes of EV-A71 (22) . The absence of preventive agents highlights the urgency of developing vaccines to prevent further fatalities caused by EV-A71.
Molecular Epidemiology of EV-A71
The complete cDNA sequences (891bp) of EV-A71 strains (VP1) isolated from various countries over a 30-year period were analyzed and divided into three distinct genotypes (A, B, C) and 11 sub-genotypes. Genotype A consists of the prototype EV-A71 BrCr strain that was identified in 1970 in USA (23) . As majority of EV-A71 viruses isolated worldwide were from genotypes B and C, they are sub-classified into sub-genotypes B1 to B5 and C1-C5 ( continually positively selected by herd immune pressure and hence, this would make it more difficult to select a vaccine strain as strain replacement was an ongoing evolutionary process.
In addition, they discussed the intra-and inter-genotypic shifts among different EV-A71 epidemics and that the circulating sub-genotypes had at least 3 different antigenic characteristics. A comparison of the VP1 sequence showed that Glu43, Thr58, Thr184 and Ser240 were signature amino acids for genotype B (B1, B4 and B5) whereas Arg22, Asp31
and Ile249 were present only for sub-genotype C2. Genotype B5 has Asp164 which had a similar signature amino acid with sub-genotypes C2 and C4 but the Asp164 was absent in B1 or B4 (31) . Such genetic changes may contribute to distinct antigenic properties of subgenotypes, although other capsid protein-coding regions may require further examinations.
Genomic changes that have an impact on antigenicity might lead to low levels of protection against different sub-genotype strains. The genomic changes introduced to mutant viruses by site-directed mutagenesis will be useful for the determination of specific effects on virulence and antigenicity.
Vaccine development

Inactivated Vaccines
A number of biopharmaceutical companies are currently at different phases of clinical trials with their inactivated vaccines (IV). There are 3 companies (Sinovac, Vigoo, CAMS) from China, one from Taiwan (NHRI) and another from Singapore (Inviragen) ( Two intramuscular doses of vaccine or placebo was administered to each vaccine candidate with a span of 28 days apart (33) .
It was reported that the vaccine efficacy from Sinovac was at 95.1% against mild HFMD and an overall efficacy rate of 94.7% was established over two years. The IV was able to produce high protection against mild EV-A71 infections for a duration of 2 years when 3
doses were given at 6, 12 and 18 months, respectively (34) . The IV from Vigoo and CAMS also showed a protective rate of 95%. Nevertheless, although the efficacy of the IVs was more than 90% against mild HFMD, there was only 80.4% protection against severe HFMD (35) .
This would mean approximately 19.6% of young children would not be conferred protection against EV-A71-associated serious disease. The IV would be able to effectively reduce the number of mild HFMD cases, but not the mortality rate among infants infected by EV-A71 strains capable of causing fatal HFMD. Hence, viral surveillance studies of emerging and endemic EV-A71 is needed to ensure the efficacy of the newly licensed EV-A71 IVs.
Sinovac and CAMS demonstrated geometric mean titers (GMT) of 165.8 (400 U/twodoses) and 170.6 (100 U/two-doses) which could induce seroconversion in > 90% of subjects (36) . The IV from Beijing Vigoo when given at 320 U/two-doses produced 325. showed that GMTs of cross-reactive NtAb titers against genotype A was lower (≥ 4-fold difference) than the sera obtained from children infected with sub-genotypes C2, C4, B4 and B5 (41) . Interestingly in another study, the NtAb titers in children induced by the EV-A71 C4a vaccine were low against several sub-genotypes, including the sub-genotype C4a, but it was able to cross-protect against sub-genotypes B4, B5, C1, C2 and C4b. All the NtAb titers induced by C4a were higher than 1:32, which would be deemed protective based on vaccine immune correlation studies (42) .
In a Taiwan study, healthy adult volunteers were vaccinated with either 5-µg and 10-µg doses of EV-A71 sub-genotype B4 strain and it induced very strong NtAb responses in > 85% of volunteers that did not have pre-existing NtAb against sub-genotypes B1, B5 and C4a.
However, the EV-A71 vaccine produced weak cross-neutralizing antibody responses (in ∼20% of participants) against sub-genotype C4b and CV-A16. Additionally, more than 90% of the vaccinees did not develop cross-neutralizing antibody responses (Nt < 8) against sub-genotype C2. The researchers discovered that about 45% of the volunteers had < 8 pre-vaccination NtAb level against the sub-genotype B4. After the first EV-A71 immunization, 95% of vaccinees had > 4-fold increase in NtAb, but there was no further increase in NtAb levels after the second booster injection. Nevertheless, this vaccine strain was able to elicit a strong NtAb response (with a NtAb range from 11 -4019) against sub-genotypes B1, B5 and C4a and could be subjected to more clinical trials for further evaluations (43) .
Further studies are needed after vaccination to have a good gauge of the ability of crossneutralization against all other EV-A71 sub-genotypes, determine the types of immune responses and understand vaccine immune correlates of protection. As CVA-16 co-circulates with EV-A71 in large HFMD outbreaks, it would be vital to produce a bivalent vaccine to reduce epidemics. Unlike the inactivated polio vaccine which comprises 3 serotypes, the EV-A71 IV produced in China only uses the C4a sub-genotype. The C4a elicited immune response was able to confer broad protection against B and C sub-genotypes. However, it also had lower immune protection against EV-A71 genotype A strains (42) . In addition, the IV did not undergo clinical trials in other multi-centres and hence, registration and standardisation would be major deterrents for the IV to be utilised in other Asia-Pacific countries (44) .
It is also pertinent to monitor cases of antibody dependent enhancement (ADE). ADE refers to sub-neutralizing concentrations of antibodies produced from maternal or previous primary infection which could exacerbate subsequent infection and lead to disease severity. In infection in animal models. They discovered that a sequential EV-A71 infection in mice led to mortality after a primary infection with a non-lethal EV-A71 strain. This is indicative of the role of ADE in the pathogenesis of infection (46) . Therefore, to prevent a disease from being exacerbated by unwanted induction of enhancing antibodies, the development of novel vaccines has to consider the detrimental effects of ADE. conditional thermostable mutants could be constructed via changing the charge characteristics of VP1 as a K215A mutation in the GH loop decreased thermal stability. Their study showed that EV-A71 infection could be impaired by the inhibition of intra-or intermolecular interactions within the VP1 protein (69) . In addition, the NIBSC scientists had constructed a genetically stable OPV strain by modifying the domain V in the 5'-NTR of the PV genome by deleting any U-G base-pairs. They deduced that mutations in domain V would generate an attenuated PV. In addition, they transferred a crucial cis-acting replication element (cre) to a position close to the 5' end from the P2 region to decrease the loss of this part of the genome via recombination (70). Hence, the genetic stability of the attenuated PV strain would be increased and it would require two recombination events to replace domain V which was highly improbable. Such an approach could be adopted to further attenuate and stabilize the EV-A71 vaccine strain.
3-Dimensional Crystal structures
The 3D crystal structures of the virus-like particles (VLPs) for EV-A71 and chimeric EV-A71/CVA16 VLPs comprised linear and conformational epitopes of EV-A71 that are mostly found in both VLPs. Lyu et al. (2014) discovered that a minimum of eighteen amino acids from the VP1 BC loop (N-terminus) were temporally externalized, making it convenient for peptide insertion to generate recombinant EV-A71 virion. These foreign peptide insertions did not affect capsid structural changes, viral replication and un-coating process (71).
Interestingly, a chimeric VLP containing substitution at four residues (K215L, E217A, K218N
and E221D) within the GH loop of the SP70 epitope induced NtAb titers against both CV-A16
and EV-A71. The original VP1 GH loop in EV-A71 VLPs demonstrated a surface charge potential difference that was markedly different from the chimeric VLP, possibly attributed by the mutations in the GH loop which made it more exposed on the viral particle surface (72). 
Bivalent and Trivalent Vaccines against Enteroviruses
The predominant enteroviruses circulating and causing frequent HFMD epidemics are EV-A71
and CV-A16. Hence, biopharmaceutical organizations such as the University of Queensland (83) . These studies showed that bivalent vaccination is indeed a promising approach for HFMD vaccine development as it has added advantages of being highly immunogenic, noninfectious, and accessible to quality control.
Nevertheless, there remains considerable interest as to which HFMD-causing serotype should be selected in a bivalent or trivalent vaccine. As EV-A71 and CV-A16 were found to co-circulate during HFMD outbreaks and most of the cases were due to EV-A71 and CV-A16, it would be desirable for a bivalent EV-A71/CV-A16 vaccine to be produced (84) . In addition, the bivalent vaccine should be able to protect against the EV-A71 sub-genotype C4 or B4 as these sub-genotypes were the predominant ones causing fatal HFMD. Moreover, NtAbs elicited by C4 and B4 have been found to cross neutralize against other EV-A71sub-genotypes (42, 85) . A study by Chou et al. (2012) demonstrated that their IV based on the sub-genotype B4 could elicit cross-neutralizing antibodies against sub-genotypes B1, B5 and C4A with NtAb titers ranging from 1:64 to 1:1280 (85) . It greatly simplifies the choice of vaccine strain for EV-A71 as immunization with one sub-genotype could potentially cross-protect against all other sub-genotypes. This is in contrast to the polio vaccine whereby 3 serotypes were required to construct the oral polio vaccine. In addition, the chosen strain should be able to grow to high titers in a FDA approved cell line.
It is also important to address any manufacturing problems that may occur in the vaccine production process. The chosen bivalent vaccine comprising EV-A71/CV-A16 strains has to show strong genetic stability during passages based on the nucleotide sequences of the master virus seed, working seed banks and virus harvested from the production lots. These nt.
sequences have to be identical with that of the original isolate (86) . It is well known that serum protein is needed for optimal growth in cells as it provides a source of nutrients and growth factors. However, large amounts of serum proteins in the cell culture medium could make downstream purification significantly more difficult. Hence, virus production from cell culture grown in serum-free (SF) medium is preferable (87) . Nevertheless, growth in SF medium may not represent optimal conditions for cell growth and high viral titer.
An outstanding manufacturing challenge would be the lack of financial support and technology transfer from foreign vaccine manufacturers. Currently, roller-bottles, cell factories and micro-carrier bioreactors are used for manufacturing bioprocesses. To produce more than 2 million EV-A71 vaccine doses annually, the micro-carrier bioreactor technology is the most ORF, open reading frame; OPV, oral poliovirus vaccine; RNA, ribonucleic acid; IV, inactivated vaccine; LAV, live attenuated vaccine; VLP, virus-like particle; GMT; Geometric mean titers; wt, wild type; 3DPol, 3D Polymerase.
